華東醫藥(000963.SZ):子公司中美華東擬收購破產重整後的華昌高科100%股權
格隆匯12月28日丨華東醫藥(000963.SZ)公佈,安徽華昌高科藥業有限公司(“華昌高科”)因不能清償到期債務且明顯缺乏清償能力,被安徽省和縣人民法院於2021年1月21日依法裁定破產重整,和縣人民法院於2021年2月2日作出決定書,指定國厚資產管理股份有限公司擔任華昌高科管理人。
公司工業微生物板塊目前面臨較好的發展機遇,為進一步擴大產業化規模,公司經多次考察並論證後認為華昌高科位於當地精細化工產業園,其現有閒置資源有較高盤活潛力,通過改造其現有設備設施,能快速形成公司工業微生物板塊所需的原料藥、高端中間體、特殊功能化學品的生產能力。
鑑於上述原因,公司全資子公司杭州中美華東製藥有限公司(“中美華東”)參與華昌高科破產重整,成為其重整投資人。2021年11月30日中美華東與管理人簽署了附條件生效的《重整投資協議》,華昌高科將在破產重整後由中美華東收購其100%股權,原股東權益將調整為零,中美華東將以增資形式投入1.08億元人民幣,用於支付和清償華昌高科《重整計劃》涉及的破產費用、共益債務及破產債權。華昌高科債權人將以法定比例受償,不能獲得清償的債權部分,中美華東及重整後的華昌高科不再負有清償義務。
除此之外,中美華東計劃對華昌高科生產線、公用系統等進行合理規劃並進行新的投入,以激活華昌高科產能並引入新產品,此部分工作預計將於2022年3月底之前完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.